1259972-62-7

Upstream product

• 556-02-5 tyrosine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 15924-16-0 (R)-2-amino-3-(3,5-dichloro-4-hydroxyphenyl)propanoic acid 

Downstream Products

• 173383-17-0 (S)-[(S)-2-Amino-3-(3,5-dichloro-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 173383-19-2 (S)-[(S)-2-{(R)-2-(4-Benzyloxy-phenyl)-2-[(R)-2-tert-butoxycarbonylamino-2-(4-hydroxy-3,5-diiodo-phenyl)-acetylamino]-acetylamino}-3-(3,5-dichloro-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 
• 173383-18-1 (S)-[(S)-2-[(R)-2-Amino-2-(4-benzyloxy-phenyl)-acetylamino]-3-(3,5-dichloro-4-hydroxy-phenyl)-propionylamino]-(3,5-dimethoxy-phenyl)-acetic acid methyl ester 

Relevant academic research and scientific papers

Structure-Activity Relationship Study of Majusculamides A and B and Their Analogues on Osteogenic Activity

We discovered that majusculamide A (1) and majusculamide B (2), isolated from a marine cyanobacterium collected in Okinawa, induced osteoblast differentiation in MC3T3-E1 cells. Although majusculamide A (1) has a different configuration only at the C-19 stereocenter, bearing a methyl group, compared to majusculamide B (2), the effect of 1 was stronger than that of 2. We synthesized some analogues of the majusculamides (3-15) and evaluated osteogenic activities of these analogues. The structure-activity relationship study of majusculamide analogues suggested that the number of methyls and configuration at C-19 and the nature of the substituent at C-20 of majusculamide A (1) may be important for the osteoblast differentiation-inducing effect of 1.